DESCRIPTION
IBC Life Sciences has been the leading provider of conferences on microarray technologies, biomarkers and molecular diagnostics for many years and with great success. Drawing upon our 15th Annual Chips to Hits®, 7th Annual Biomarkers, and 7th annual Molecular Diagnostics meetings, we have developed the Discovery2Diagnostics Conference & Exhibition to reflect recent changes in these industries and to capture opportunities presented by the fast-paced developments in technologies and research throughout the discovery to diagnostics spectrum.
We have expanded the scope of this meeting to include more RNAi related research and development as it affects sequencing and detection technologies, biomarkers and molecular diagnostics, recent work to deliver point-of-care (or near POC) molecular diagnostics and sessions with panel discussions on related regulatory and reimbursement issues. The challenges experienced by those involved in the Discovery2Diagnostics spectrum and the enabling breakthroughs that bridge the gap between biomarkers and molecular diagnostics in the R&D setting and the clinic will also be explored.
Pathways to Biomarker and Diagnostics Reimbursement
10:30 Overview
Biomarkers are poised to redefine many aspects of health care practice and policy. More than virtually any other factor, reimbursement will play a pivotal role in the success of biomarker-based technologies and personalized medicine approaches. This session will explore current practice and policy issues related to reimbursement of biomarkers, including:
- The changing reimbursement environment for biomarkers and value of reimbursement planning early in the product life cycle
- The importance of planning from a reimbursement perspective
- Making a strong value case to optimize pricing and reimbursement opportunities and minimize risks to adoption and diffusion
Eric Faulkner, Ph.D., MPH, Director of US Reimbursement and Market Access, RTI Health Solutions
11:00 Venture Capitalist Perspectives on Investment in Biomarker-based Technologies: How Important is Reimbursement Potential?
TBA
11:30 Payor Perspective: Analytical and Clinical Metrics used in the Health Technology Assessment Process
The revolution of lower-cost molecular biology means that today, very sophisticated biomarker-based tests reach the clinical marketplace with substantial validation data within a few years of discovery. This session will evaluate diagnostics reimbursement from the payer perspective and discuss challenges that are faced when molecular innovation outruns legacy coding, coverage and payment systems for diagnostics reimbursement and how to work toward a winning strategy despite market uncertainties.
Bruce Quinn, MD, Ph.D., Senior Health Policy Specialist, Foley Hoag, LLC
12:00 Networking Luncheon, Exhibit and Poster Viewing
1:25 Diagnostics Industry Perspective: Planning for Reimbursement
There is a significant need educate payers and other health decision makers on the value of appropriate coverage and reimbursement of molecular diagnostics. A fully integrated personalized medicine paradigm will be driven by the ability to eliminate the reimbursement and coverage barriers that impact a patient's ability to access technological innovations in biomarker-based tests. This session will explore the challenges of obtaining appropriate reimbursement from the perspective of the diagnostics manufacturer and offer suggestions for overcoming obstacles to reimbursement.
John R. Ridge, National Director, Managed Care and Reimbursement, diaDexus, Inc.
2:00 Panel Discussion
Eric Faulkner, Ph.D., MPH, Director of US Reimbursement and Market Access, RTI Health Solutions
John R. Ridge, National Director, Managed Care and Reimbursement, diaDexus, Inc.
Bruce Quinn, MD, Ph.D., Senior Health Policy Specialist, Foley Hoag, LLC
2:30 Networking Coffee Break, Exhibit and Poster Viewing
For full conference agenda please click here
COST: http://www.ibclifesciences.com/D8176/pricing.xml